HUP9800028A2 - Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének - Google Patents

Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének

Info

Publication number
HUP9800028A2
HUP9800028A2 HU9800028A HUP9800028A HUP9800028A2 HU P9800028 A2 HUP9800028 A2 HU P9800028A2 HU 9800028 A HU9800028 A HU 9800028A HU P9800028 A HUP9800028 A HU P9800028A HU P9800028 A2 HUP9800028 A2 HU P9800028A2
Authority
HU
Hungary
Prior art keywords
cells
genes
mag
physiological
expression
Prior art date
Application number
HU9800028A
Other languages
English (en)
Inventor
Jörn Bullerdiek
Original Assignee
K.U. Leuven Research & Development
Jörn Bullerdiek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220025&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9800028(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by K.U. Leuven Research & Development, Jörn Bullerdiek filed Critical K.U. Leuven Research & Development
Publication of HUP9800028A2 publication Critical patent/HUP9800028A2/hu
Publication of HUP9800028A3 publication Critical patent/HUP9800028A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

A találmány tárgyát az úgynevezett MAG- (Műlti-tűmőr Aberrant Grőwth:több tűmőr esetében rendellenes sejtszapőrődás előidézébenközrejátszó) gének képezik, tővábbá a fenti gének által kódőltprőteinek, a MAG-gének származékai, és azők alkalmazása, valaminteljárásők nemfiziőlógiás prőliferációs képességgel rendelkező sejtekkiműtatására, és ilyen sejtek jelenlétével jellemezhető betegségekkezelésére. A találmány tárgyát képezik tővábbá a MAG-gének expresszióját módősítóvegyületek és azők terápiás célra történő alkalmazása, valamintdiagnősztikai reagenskészletek, nem-fiziőlógiás prőliferációsképességgel rendelkező sejtek kiműtatására, és gyógyászati készít-mények, MAG-gének szárazékai expressziójának csökkentésére. A találmány szerinti megőldás alkalmas nem-fiziőlógiás prő- liferációsképességgel rendelkező sejtek kiműtatására, és ilyen sejtekjelenlétével jellemezhető betegségek vagy rendellenességekkiműtatására és/vagy kezelésére. ŕ
HU9800028A 1995-02-17 1996-02-19 Multiple-tumor aberrant growth genes HUP9800028A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95200390 1995-02-17
EP95201951A EP0727487A1 (en) 1995-02-17 1995-07-14 Multiple-tumor aberrant growth genes

Publications (2)

Publication Number Publication Date
HUP9800028A2 true HUP9800028A2 (hu) 1998-04-28
HUP9800028A3 HUP9800028A3 (en) 2001-02-28

Family

ID=8220025

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9800028A HUP9800028A3 (en) 1995-02-17 1996-02-19 Multiple-tumor aberrant growth genes

Country Status (14)

Country Link
US (3) US6544784B1 (hu)
EP (3) EP0727487A1 (hu)
JP (4) JPH11500614A (hu)
KR (1) KR19980702276A (hu)
AT (1) ATE338114T1 (hu)
AU (1) AU4879096A (hu)
CA (1) CA2213237A1 (hu)
CZ (1) CZ247597A3 (hu)
DE (2) DE69636495T2 (hu)
FI (1) FI973354A (hu)
HU (1) HUP9800028A3 (hu)
NO (1) NO973685L (hu)
PL (1) PL321831A1 (hu)
WO (1) WO1996025493A1 (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548122A1 (de) * 1995-12-21 1997-06-26 Joern Prof Dr Bullerdiek Nukleinsäuresequenzen von Genen der High Mobility Group Proteine sowie Verwendungen derselben
US6323329B1 (en) 1995-12-21 2001-11-27 Jorn Bullerdiek Nucleic acid sequences of genes encoding high mobility group proteins
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6171779B1 (en) 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
AU748743B2 (en) * 1997-05-07 2002-06-13 University Of Medicine And Dentistry Of New Jersey Hmgi proteins in tumors and obesity
EP0878552A1 (en) * 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molecular detection of chromosome aberrations
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
WO1999006563A1 (en) 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
AU3516899A (en) * 1998-05-04 1999-11-23 Dako A/S Method and probes for the detection of chromosome aberrations
WO1999057012A2 (de) 1998-05-05 1999-11-11 Elau Elektronik Automations Ag Verpackungsmaschine
IT1299583B1 (it) * 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
DE19904514A1 (de) * 1999-02-04 2000-08-10 Joern Bullerdiek Mittel zur Prävention und/oder Behandlung von Leiomyomen
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
EP1412754A4 (en) * 2001-06-27 2005-10-19 Inst Medical W & E Hall DIAGNOSTIC PROCEDURE AND AGENTS
DE50212280D1 (de) * 2001-12-19 2008-06-26 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
US20030219742A1 (en) * 2002-03-29 2003-11-27 Sanjay Bhanot Antisense modulation of HMGI-C expression
EP1519725A4 (en) * 2002-04-05 2005-08-10 Cyternex Inc PROCESS FOR TARGETING QUADRUPLEX DNA
US7405041B2 (en) * 2002-08-20 2008-07-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for regulating transcription by targeting quadruplex DNA
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7288250B2 (en) 2003-09-11 2007-10-30 Critical Therapeutics, Inc. Monoclonal antibodies against HMGB1
US8415315B2 (en) 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
AU2005333602B2 (en) 2004-10-22 2012-04-12 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
CA2631212A1 (en) 2005-11-28 2007-07-05 Medimmune, Llc Antagonists of hmgb1 and/or rage and methods of use thereof
JP5225109B2 (ja) 2007-02-15 2013-07-03 国立大学法人 熊本大学 ヒトｈｍｇｂ−１に特異的に結合する抗体を有効成分として含有する治療剤
JP5366039B2 (ja) * 2008-03-18 2013-12-11 株式会社常光 悪性腫瘍の予想、診断のための方法および組成物
US20100297649A1 (en) * 2009-04-22 2010-11-25 Oliveira Andre M Methods and materials for detecting gene amplification
EP2764118A1 (en) 2011-10-05 2014-08-13 University of Bremen Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
US20180127831A1 (en) * 2015-05-21 2018-05-10 Université de Montréal Prognostic markers of acute myeloid leukemia survival

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62166897A (ja) * 1986-01-20 1987-07-23 Toyo Soda Mfg Co Ltd 核内非ヒストン蛋白質に対するモノクロ−ナル抗体
EP0498827B1 (en) * 1989-11-02 2001-08-01 DictyTech Pty Limited Improved plasmid vectors for cellular slime moulds of the genus dictyostelium
US5756307A (en) * 1991-09-20 1998-05-26 The United States Of America As Represented By The Department Of Health And Human Services Sequence of human dopamine transporter cDNA
US6171779B1 (en) * 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer

Also Published As

Publication number Publication date
WO1996025493A1 (en) 1996-08-22
US20030190285A1 (en) 2003-10-09
JP2007082549A (ja) 2007-04-05
JPH11500614A (ja) 1999-01-19
EP1762619A3 (en) 2007-05-09
EP1762619A2 (en) 2007-03-14
EP0811061B1 (en) 2006-08-30
JP2008099698A (ja) 2008-05-01
DE69636495D1 (de) 2006-10-12
NO973685L (no) 1997-10-17
US6544784B1 (en) 2003-04-08
JP2009254378A (ja) 2009-11-05
US20110318834A1 (en) 2011-12-29
AU4879096A (en) 1996-09-04
KR19980702276A (ko) 1998-07-15
ATE338114T1 (de) 2006-09-15
EP1762619B1 (en) 2013-06-26
FI973354A0 (fi) 1997-08-15
DE69636495T2 (de) 2007-05-24
FI973354A (fi) 1997-10-16
EP0811061A1 (en) 1997-12-10
CZ247597A3 (cs) 1998-07-15
CA2213237A1 (en) 1996-08-22
HUP9800028A3 (en) 2001-02-28
PL321831A1 (en) 1997-12-22
EP0811061B2 (en) 2010-07-21
EP0727487A1 (en) 1996-08-21
DE811061T1 (de) 2002-10-17
NO973685D0 (no) 1997-08-11

Similar Documents

Publication Publication Date Title
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
BR0010648A (pt) Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril
ATE65505T1 (de) Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.
BR9910251A (pt) Estimulação hematopoiética
HUP9702388A2 (hu) Növekedésihormon-kibocsátást serkentő vegyületek és ezeket tartalmazó gyógyszerkészítmények
ES2180555T3 (es) Nueva substancia fisiologicamente activa.
ES2147720T3 (es) Factor de celulas madre.
ATE237339T1 (de) Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen
DE69526853D1 (de) Hemmung der fortpflanzung von arterienglattmuskelzellen
DE60126495D1 (de) Nukleinsäure und protein, genannt 158p1d7, für die behandlung und erkennung von blasenkrebs und anderen krebsarten
DE69424777T2 (de) 3,4-diarylchromane zur behandlung von dermatitis
DE58901002D1 (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
DK0689586T3 (da) VPR-funktion og -aktivitet
HUT58037A (en) Process for producing n-2,3-butadienyl tri- and tetraaminoalkane derivatives
HUP9901188A2 (hu) Új, meghatározott enzimkeverékek sejtkinyeréshez és sebkezeléshez
AU678343B2 (en) Method and composition for determining the immunological activity of bioactive substances
PT883406E (pt) Utilizacao da il-7 no tratamento das doencas auto-imunes em particular a diabetes mellitus insulinodependente
Müller Influence of ionizing radiation on the appearance in the serum of rabbits of humoral factors slowing down cell division
DE3650368D1 (de) Verwendung von Depogen zur Behandlung von eingeschränktem Blutkreislauf.
TR199901385T2 (xx) Piperidin t�revleri.
SU1613956A1 (ru) Средство дл модул ции функциональной активности естественных киллеров IN VIтRо
SU1684670A1 (ru) Способ определени индивидуальной чувствительности к гипербарической оксигенации
BR9709379A (pt) Uso de uridina, e, composição para o tratamento de distúrbios do sistema nervoso devido à degeneração seletiva de células neuroniais ou gliais em mamìferos.
MD1119G2 (ro) Metodă de tratament al afecţiunilor inflamatorii ale organelor genitale feminine